|Synonyms||(2E)-2-[1-(3-Bromophenyl)ethylidene]α-(benzoylamino)-3,4-dihydro-4-oxo-1-phthalazineaceticacidhydrazide;AC 55541;alpha-(Benzoylamino)-3,4-dihydro-4-oxo-1-phthalazineacetic acid (2E)-2-[1-(3-bromophenyl)ethylidene]hydrazide;N-[2-[(2E)-2-[1-(3-bromophenyl)ethylidene]hydrazinyl]-2-oxo-1-(4-oxo-3H-phthalazin-1-yl)ethyl]benzamide|
|Description||AC-55541 is a novel small-molecule protease-activated receptor 2(PAR2) agonist which displays no activity at other PAR subtypes or at over 30 other receptors involved in nociception and inflammation. It activated PAR2 signaling in cellular proliferation assays, phosphatidylinositol hydrolysis assays, and Ca(2+) mobilization assays, with potencies ranging from 200 to 1000 nM. It was well absorbed when administered intraperitoneally to rats, reaching micromolar peak plasma concentrations. It was stable to metabolism by liver microsomes and maintained sustained exposure in rats.|
|Quantity||Grams to Kilograms|
|Quality Standard||In-house standard|
|Targets||Protease-Activated Receptors (PARs)|
BMS-986120, an imidazoles derivative, has been found to be a PAR4 antagonist that could probably be effective against thrombus propagation and pathological vasc...
AC-55541 is a novel small-molecule protease-activated receptor 2(PAR2) agonist which displays no activity at other PAR subtypes or at over 30 other receptors in...
Thrombin Receptor Activator Peptide 6
TRAP-6, a peptide compound, has been found to be a PAR1 agonist and could also influence the phosphorylation of rapid phosphodiesterase 3A in the positive way.
SCH-530348 is a novel antiplatelet agent undergoing development by Schering-Plough Corp for the treatment and prevention of atherothrombosis. It is currently un...
Atopaxar is a Protease-activated receptor-1 (PAR-1) inhibitor. It can inhibit the binding of a high-affinity thrombin receptor-activating peptide ([(3)H]haTRAP)...